Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution

Rugmani Padmanabhan Iyer, Lisandra E. de Castro Brás, Nicolle L. Patterson, Manishabrata Bhowmick, Elizabeth R. Flynn, Majdouline Asher, Presley L. Cannon, Kristine Y. Deleon-Pennell, Gregg B. Fields, Merry L. Lindsey

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Matrix metalloproteinase-9 (MMP-9) is robustly elevated in the first week post-myocardial infarction (MI). Targeted deletion of the MMP-9 gene attenuates cardiac remodeling post-MI by reducing macrophage infiltration and collagen accumulation through increased apoptosis and reduced inflammation. In this study, we used a translational experimental design to determine whether selective MMP-9 inhibition early post-MI would be an effective therapeutic strategy in mice. We enrolled male C57BL/6J mice (3–6 months old, n = 116) for this study. Mice were subjected to coronary artery ligation. Saline or MMP-9 inhibitor (MMP-9i; 0.03 μg/day) treatment was initiated at 3 h post-MI and the mice were sacrificed at day (D) 1 or 7 post-MI. MMP-9i reduced MMP-9 activity by 31 ± 1% at D1 post-MI (p < 0.05 vs saline) and did not affect survival or infarct area. Surprisingly, MMP-9i treatment increased infarct wall thinning and worsened cardiac function at D7 post-MI. While MMP-9i enhanced neutrophil infiltration at D1 and macrophage infiltration at D7 post-MI, CD36 levels were lower in MMP-9i compared to saline, signifying reduced phagocytic potential per macrophage. Escalation and prolongation of the inflammatory response at D7 post-MI in the MMP-9i group was evident by increased expression of 18 pro-inflammatory cytokines (all p < 0.05). MMP-9i reduced cleaved caspase 3 levels at D7 post-MI, consistent with reduced apoptosis and defective inflammation resolution. Because MMP-9i effects on inflammatory cells were significantly different from previously observed MMP-9 null mechanisms, we evaluated pre-MI (baseline) systemic differences between C57BL/6J and MMP-9 null plasma. By mass spectrometry, 34 plasma proteins were significantly different between groups, revealing a previously unappreciated altered baseline environment pre-MI when MMP-9 was deleted. In conclusion, early MMP-9 inhibition delayed inflammation resolution and exacerbated cardiac dysfunction, highlighting the importance of using translational approaches in mice.

Original languageEnglish (US)
Pages (from-to)109-117
Number of pages9
JournalJournal of Molecular and Cellular Cardiology
Volume100
DOIs
StatePublished - Nov 1 2016

    Fingerprint

Keywords

  • Apoptosis
  • Inhibitor
  • MMP-9
  • Macrophage
  • Myocardial infarction
  • Neutrophil
  • Proteomics

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

Iyer, R. P., de Castro Brás, L. E., Patterson, N. L., Bhowmick, M., Flynn, E. R., Asher, M., Cannon, P. L., Deleon-Pennell, K. Y., Fields, G. B., & Lindsey, M. L. (2016). Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution. Journal of Molecular and Cellular Cardiology, 100, 109-117. https://doi.org/10.1016/j.yjmcc.2016.10.005